Blog
Pharma's hunt for academic innovation
Pharma overlooks many potentially valuable collaborations by focusing exclusively on the academic "A-list".
Enabling R&D collaborations between academia and pharma
Many academic researchers aren't aware of opportunities to collaborate with pharma R&D organizations - so we created a directory to help them. Check it out!
The case for "biotech paranoia"
Biotechs need to get anxious - really anxious - about how changes in the industry will affect Pharma deal-making.
Making clinical development more investable with “financially adaptive trials”
Clinical trials are a terrible investment. But fear not – in our NRDD article, we show a path forward.
Should pharma R&D and commercial "just be friends"?
GlaxoSmithKline is giving up its commercial presence in oncology, but keeping cancer R&D. This could be a huge deal, and a harbinger of things to come.
"Saving the winners" to improve pharma R&D
Adaptive trials could be a way to improve the pharma industry's dismal R&D success rates.
Cancer R&D's tenuous value chain
To succeed in oncology drug development, Pharma execs need new approaches to clinical trials, diagnostics and pricing.
New drugs less effective than old ones? Not so fast (continued)
A recently-published screed about pharma R&D plumbs new depths in pharmascolding. Let's see if it holds up to scrutiny. (Want to take a wild guess?)
New drugs less effective than old ones? Not so fast...
Q: Are we really making worse drugs now than we used to, as suggested by a recent high-profile news article? A: No. And I'll explain why.
Oncology combinations – four key elements to biopharma success
If Pharma companies want to succeed in cancer R&D, they need to get better at handling combinations. Here are some places to start.